Diplatin, a Novel and Low-Toxicity Anti-Lung Cancer Platinum Complex, Activation of Cell Death in Tumors via a ROS/JNK/p53-Dependent Pathway, and a Low Rate of Acquired Treatment Resistance

Background: Platinum-based drugs prevail as the main treatment of lung cancer; this is caused by their relative effectiveness despite known side effects, such as neurotoxicity. The risk reward of the treatment and side effects is confronted when dosage is considered and when resistance to treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xixi, Jia, Yongliang, Dong, Xinwei, Shen, Jian, Jin, Yachao, Li, Yanyou, Wang, Fang, Anenberg, Eitan, Zhou, Jiancang, Zhu, Jianping, Chen, Xiaoping, Xie, Qiangmin, Xie, Yicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749073/
https://www.ncbi.nlm.nih.gov/pubmed/31572176
http://dx.doi.org/10.3389/fphar.2019.00982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749073/
https://www.ncbi.nlm.nih.gov/pubmed/31572176
http://dx.doi.org/10.3389/fphar.2019.00982

Ejemplares similares